These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 37143361)
1. Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic. Chu W; Houston ZH; Fletcher NL; Huda P; Ahamed M; Lim TX; Day BW; Pinkham M; Thurecht KJ Biomacromolecules; 2023 Jun; 24(6):2674-2690. PubMed ID: 37143361 [TBL] [Abstract][Full Text] [Related]
2. Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma. Chen X; Zheng Y; Zhang Q; Chen Q; Chen Z; Wu D J Nanobiotechnology; 2024 May; 22(1):264. PubMed ID: 38760771 [TBL] [Abstract][Full Text] [Related]
3. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study. Yu Y; Wang A; Wang S; Sun Y; Chu L; Zhou L; Yang X; Liu X; Sha C; Sun K; Xu L Mol Pharm; 2022 Apr; 19(4):1219-1229. PubMed ID: 35262365 [TBL] [Abstract][Full Text] [Related]
5. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma. Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164 [TBL] [Abstract][Full Text] [Related]
6. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression. Zhao W; Yun K Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776 [TBL] [Abstract][Full Text] [Related]
7. Membrane-Decorated Exosomes for Combination Drug Delivery and Improved Glioma Therapy. Liang S; Xu H; Ye BC Langmuir; 2022 Jan; 38(1):299-308. PubMed ID: 34936368 [TBL] [Abstract][Full Text] [Related]
8. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition. Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243 [TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide. Sukumar UK; Bose RJC; Malhotra M; Babikir HA; Afjei R; Robinson E; Zeng Y; Chang E; Habte F; Sinclair R; Gambhir SS; Massoud TF; Paulmurugan R Biomaterials; 2019 Oct; 218():119342. PubMed ID: 31326657 [TBL] [Abstract][Full Text] [Related]
10. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527 [TBL] [Abstract][Full Text] [Related]
11. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle. Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038 [TBL] [Abstract][Full Text] [Related]
12. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
13. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance. Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522 [TBL] [Abstract][Full Text] [Related]
14. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. Yamamuro S; Takahashi M; Satomi K; Sasaki N; Kobayashi T; Uchida E; Kawauchi D; Nakano T; Fujii T; Narita Y; Kondo A; Wada K; Yoshino A; Ichimura K; Tomiyama A Cancer Sci; 2021 Nov; 112(11):4736-4747. PubMed ID: 34536314 [TBL] [Abstract][Full Text] [Related]
15. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605 [TBL] [Abstract][Full Text] [Related]
16. Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. Ward SM; Skinner M; Saha B; Emrick T Mol Pharm; 2018 Nov; 15(11):5263-5276. PubMed ID: 30354145 [TBL] [Abstract][Full Text] [Related]
17. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
18. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
19. Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy. Zou Y; Wang Y; Xu S; Liu Y; Yin J; Lovejoy DB; Zheng M; Liang XJ; Park JB; Efremov YM; Ulasov I; Shi B Adv Mater; 2022 Aug; 34(33):e2203958. PubMed ID: 35738390 [TBL] [Abstract][Full Text] [Related]
20. Lnc-TALC promotes O Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]